Media Articles Related to Panretin (Alitretinoin Topical)
Ocriplasmin Injection Linked to Impaired Vision
Source: Medscape Ophthalmology Headlines [2014.03.04]
Two case reports add to previous reports and link ocriplasmin for the treatment of symptomatic vitreomacular adhesion with impaired vision and panretinal changes.
Medscape Medical News
Published Studies Related to Panretin (Alitretinoin Topical)
Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A. [2011.04]
BACKGROUND: Based on in vitro data with isolated cytochrome P450 (CYP) isoenzymes, alitretinoin interacts only with CYP3A4, and the potential for drug-drug interactions is considered negligible. AIM: To confirm in humans the lack of potential interactions between CYP3A4 and alitretinoin in vivo... CONCLUSIONS: Single and repeated doses of alitretinoin do not alter the PK of ciclosporin A and ketoconazole. Simvastatin levels were slightly but significantly reduced by co-administration of alitretinoin. Substrates of CYP3A4 did not affect the PK of alitretinoin. However, ketoconazole significantly increased the plasma levels of alitretinoin, therefore, co-administration with CYP3A4 inhibitors such as ketoconazole may require a dose reduction of alitretinoin. (c) 2011 The Author(s). Clinical and Experimental Dermatology (c) 2011 British Association of Dermatologists.
Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective. [2010.06.25]
BACKGROUND: The impact on patients suffering from chronic hand eczema (CHE) is enormous, as no licensed systemic treatment option with proven efficacy for CHE is available. Alitretinoin is a novel agent which showed high clinical efficacy in patients with severe, refractory CHE. We assessed the cost-effectiveness of alitretinoin for CHE patient treatment from a Swiss third party payer perspective. A further objective of this study was to determine the burden of disease in Switzerland... CONCLUSION: The therapy for CHE patients is currently insufficient. In our long-term model we identified the treatment with alitretinoin as a cost-effective alternative for the therapy of CHE patients in Switzerland.
Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. [2010.02.01]
BACKGROUND: Patients with severe chronic hand eczema (CHE) often respond to therapy with oral alitretinoin (9-cis retinoic acid). However, the efficacy of alitretinoin after disease relapse has not been demonstrated. OBJECTIVES: To assess the efficacy and safety of a second course of oral alitretinoin in patients with severe CHE who relapsed after achieving 'clear' or 'almost clear' hands following a previous course of alitretinoin... CONCLUSIONS: The majority of patients with CHE who previously achieved 'clear' or 'almost clear' hands following treatment with alitretinoin 30 mg per day also responded to a second course of treatment. Retreatment was well tolerated. Intermittent treatment with alitretinoin is suitable for the long-term management of CHE.
Alitretinoin for severe chronic hand Eczema: a NICE single technology appraisal. 
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of alitretinoin (Basilea Pharmaceuticals Ltd, Basel, Switzerland) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with severe chronic hand eczema (CHE), as part of the Institute's single technology appraisal (STA) process...
Successful retreatment with alitretinoin in patients with relapsed chronic hand
'almost clear' hands following a previous course of alitretinoin... CONCLUSIONS: The majority of patients with CHE who previously achieved 'clear' or
Clinical Trials Related to Panretin (Alitretinoin Topical)
Efficacy and Safety of Oral Alitretinoin (Toctinoï¿½) in the Treatment of Patients With Cutaneous Lupus Erythematosus [Not yet recruiting]
To evaluate the therapeutic effect of oral alitretinoin (Toctino®) in the treatment of CLE
with respect to proportion of responders based on the Revised Cutaneous Lupus Disease Area
and Severity Index (RCLASI) activity score for skin lesions at baseline and after 24 weeks
of treatment or at the latest assessment for patients who withdrew prematurely. Response is
defined as a reduction of 50% in the total RCLASI compared to the baseline value ("RCLASI
Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin [Recruiting]
This is a single center, prospective, open label, single arm, investigator initiated pilot
study investigating the effect of alitretinoin on severe lichen planus with mucosal
manifestations. The target population comprises patients with MLP for at least 3 months,
with or without LP lesions on other areas of the skin, who are refractory to topical therapy
and standard skin care, and who are otherwise in good health. Patients will be recruited at
the outpatient clinic of the dermatology department, University hospital Zurich. The planned
duration of the study is 2 years. A total of 20 patients will be included. Patients who meet
enrolment criteria will receive 30mg alitretinoin, given orally as gelatin capsules, once
daily for 24 weeks. Dose interruptions are permitted in response to adverse effects,
consistent with use of retinoids and the product label.
Most clinical evaluations will be performed every 4 weeks. A safety follow-up visit is
planned 4 weeks after the end of treatment. Further follow-up visits will be conducted 16
and 24 weeks after end of treatment in those patients meeting the primary endpoint
- Trial with medicinal product
Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis [Recruiting]
Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis. [Not yet recruiting]
The purpose of this study is to investigate the comparative efficacy, safety and efficiency
of ciclosporin microemulsion and alitretinoin in adults with severe atopic hand dermatitis.
A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients [Completed]
This is a dosage escalation study to estimate the maximum tolerated dose of 9-cis-retinoic
acid given in combination with tamoxifen. Groups of 3 to 6 patients receive oral
9-cis-retinoic acid daily for 4 weeks, after which daily oral tamoxifen is added to the
regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the
study if medically appropriate.